Glatiramer acetate is one of the known MS medications which is being used to control relapses from a long time ago and different clinical trials have shown its partial efficacy among MS patients. On the other hand, rituximab is one of the medications which is recently suggested for treatment of MS and currently phase II clinical trials are conducted to evaluate the efficacy of this medication among patients. As previously stated, there is a lack of clinical trials to compare the efficacy of suggested medications among progressive patients. To fill this gap, we aimed to compare the efficacy of these two medications on annualized relapse rate, disability, and Gad-enhanced brain lesions among patients with active progressive MS through a randomized clinical trial during a one-year follow-up period.